Topic: antipsychotic

Intra-Cellular Therapies raised its target of $150 million, which will help it prepare for an FDA filing for lumateperone in schizophrenia next year.

Check out Friday's dose of biotech's news of note.

Alkermes has cleared the first major hurdle in its bid to advance schizophrenia candidate ALKS 3831, showing an improvement over placebo in its first phase 3 trial—but a much bigger test is still to come.